BDSX Key Statistics, Chart & Performance
The current stock price of BDSX is 10.12 USD. In the past month the price increased by 62.46%. In the past year, price decreased by -46.21%.
BDSX Technical Analysis
ChartMill assigns a technical rating of 7 / 10 to BDSX. When comparing the yearly performance of all stocks, BDSX turns out to be only a medium performer in the overall market: it outperformed 62.05% of all stocks.
BDSX Fundamental Analysis
ChartMill assigns a fundamental rating of 3 / 10 to BDSX. Both the profitability and financial health of BDSX have multiple concerns.
BDSX Financial Highlights
Over the last trailing twelve months BDSX reported a non-GAAP Earnings per Share(EPS) of -5.56. The EPS increased by 28.72% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | N/A | ||
| ROA | -44.56% | ||
| ROE | N/A | ||
| Debt/Equity | N/A |
BDSX Forecast & Estimates
11 analysts have analysed BDSX and the average price target is 33.15 USD. This implies a price increase of 227.57% is expected in the next year compared to the current price of 10.12.
For the next year, analysts expect an EPS growth of 17.09% and a revenue growth 20.62% for BDSX
BDSX Ownership
BDSX Latest News, Press Relases and Analysis
About BDSX
Company Profile
Biodesix, Inc. provides blood-based diagnostics services for patients with lung disease. The company is headquartered in Louisville, Colorado and currently employs 273 full-time employees. The company went IPO on 2020-10-28. Biodesix Diagnostic Tests, marketed as Nodify Lung Nodule Risk Assessment and IQLung Cancer Treatment Guidance, support clinical decisions to expedite personalized care and improve outcomes for patients with lung disease. Biodesix Development Services enable biopharmaceutical, life sciences, and research institutions with scientific, technological, and operational capabilities that fuel the development of diagnostic tests, tools, and therapeutics. The Nodify Lung Nodule Risk Assessment assesses a suspicious lung nodule's risk of lung cancer to help identify the most appropriate treatment pathway. Nodify CDT and Nodify XL2 tests are marketed as Nodify Lung Nodule Risk Assessment. The Nodify CDT test is a blood-based test that detects the presence of seven autoantibodies associated with the presence of tumors. GeneStrat ddPCR, GeneStrat NGS and VeriStrat tests are marketed as part of its IQLung testing strategy.
Company Info
BIODESIX INC
919 West Dillon Road
Louisville COLORADO US
Employees: 273
Phone: 13034170500
BIODESIX INC / BDSX FAQ
Can you describe the business of BIODESIX INC?
Biodesix, Inc. provides blood-based diagnostics services for patients with lung disease. The company is headquartered in Louisville, Colorado and currently employs 273 full-time employees. The company went IPO on 2020-10-28. Biodesix Diagnostic Tests, marketed as Nodify Lung Nodule Risk Assessment and IQLung Cancer Treatment Guidance, support clinical decisions to expedite personalized care and improve outcomes for patients with lung disease. Biodesix Development Services enable biopharmaceutical, life sciences, and research institutions with scientific, technological, and operational capabilities that fuel the development of diagnostic tests, tools, and therapeutics. The Nodify Lung Nodule Risk Assessment assesses a suspicious lung nodule's risk of lung cancer to help identify the most appropriate treatment pathway. Nodify CDT and Nodify XL2 tests are marketed as Nodify Lung Nodule Risk Assessment. The Nodify CDT test is a blood-based test that detects the presence of seven autoantibodies associated with the presence of tumors. GeneStrat ddPCR, GeneStrat NGS and VeriStrat tests are marketed as part of its IQLung testing strategy.
What is the stock price of BIODESIX INC today?
The current stock price of BDSX is 10.12 USD. The price decreased by -8.66% in the last trading session.
What is the dividend status of BIODESIX INC?
BDSX does not pay a dividend.
What is the ChartMill technical and fundamental rating of BDSX stock?
BDSX has a ChartMill Technical rating of 7 out of 10 and a ChartMill Fundamental rating of 3 out of 10.
Where is BIODESIX INC (BDSX) stock traded?
BDSX stock is listed on the Nasdaq exchange.
How is the market expecting BDSX stock to perform?
11 analysts have analysed BDSX and the average price target is 33.15 USD. This implies a price increase of 227.57% is expected in the next year compared to the current price of 10.12.
How many employees does BIODESIX INC have?
BIODESIX INC (BDSX) currently has 273 employees.